Dual-Antigen-Targeting on Bioeconhttps://en.bioecon.ru/technologies/dual-antigen-targeting/Recent content in Dual-Antigen-Targeting on BioeconHugoen-USSat, 11 Jul 2026 13:59:31 +0700Bispecific & multispecific antibodieshttps://en.bioecon.ru/technology/bispecific-antibodies/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/bispecific-antibodies/Engineered antibodies that bind two (or more) antigens on one molecule — most powerfully a CD3 arm that recruits the patient’s own T cells to a tumour cell — delivered off-the-shelf as approved drugs across lymphoma and myeloma by Roche, Janssen, Regeneron, AbbVie/Genmab and BeiGene.